Arcus Biosciences stock
RCUSNYSEArcus Biosciences, Inc., HealthcareISIN US03969F1093
30Score 30 out of 100, Weak
Price and trend
40 / 100
Price history
−11% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 27% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 45).
The price is 44% below its 52-week high. Largest decline in 9 years: 86% (November 2021 to April 2025).
Chart figures for advanced users
- SMA 50$22.87
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$24.49
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)45
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$17.69
- The lowest closing price of the last twelve months.
- Resistance$31.57
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Arcus Biosciences, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $2.56B, is number 109 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $247M (down 4.3% year on year) and a loss of $353M.
- For fiscal 2026, analysts expect on average revenue of $73.15M (down 70.4%) and adjusted earnings per share of −$3.55.
Show more
- MEQIRI Score 30 out of 100 (Weak): rank 693 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $630M, financial debt $102M.Stability 54
Weaknesses
- DilutionShare count up 96% since 2020.Capital allocation 18
- Loss-makingLoss of $445M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$466M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 58.3% on the twelve months before. Revenue turned from negative at the start of the period to positive ($247M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 96%, operating −156%, net −143%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported −$1.00 (expected −$0.89)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$3.55+0.3%
- Revenue
- $73.15M−6.3%
- Earnings per share
- −$3.29+1.6%
- Revenue
- $52.4M−6.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −1.6%2026 revenue is expected at $65 to $75 million, with lower collaboration revenue ahead as a program winds down, and R&D spending expected to drop meaningfully in 2026 and 2027.
“We recognized GAAP revenue for the second quarter of $41 million and now expect full year 2026 GAAP revenue of $65 to $75 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $3.06M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Azoy AlexanderSale
21 Aug 2026, Chief Accounting Officer
- Shares
- 2,827
- Price
- $30.00
- Value
- $84,810
- Jaen Juan C.Sale
10 Jul 2026, President
- Shares
- 20,067
- Price
- $28.62
- Value
- $574,288
- Jaen Juan C.Sale
9 Jul 2026, President
- Shares
- 48,502
- Price
- $30.05
- Value
- $1.46M
Show 4 more
- Jaen Juan C.Sale
24 Jun 2026, President
- Shares
- 6,431
- Price
- $29.66
- Value
- $190,740
- Jaen Juan C.Sale
23 Jun 2026, President
- Shares
- 15,764
- Price
- $27.73
- Value
- $437,100
- Jaen Juan C.Sale
22 Jun 2026, President
- Shares
- 9,236
- Price
- $27.03
- Value
- $249,661
- Azoy AlexanderSale
1 Jun 2026, Chief Accounting Officer
- Shares
- 2,562
- Price
- $25.77
- Value
- $66,024
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Arcus Biosciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 30
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Zai LabZLAB $2.98B49
- ADMA BiologicsADMA $2.93B71
- MBX BiosciencesMBX $2.87B47
- BioArcticBIOA-B.ST $2.81B60
- Bavarian NordicBAVA.CO $2.69B71
- Beam TherapeuticsBEAM $2.67B41
- NewAmsterdam PharmaNAMS $2.48B35
- Zealand PharmaZEAL.CO $2.42B59
ETFs that hold Arcus Biosciences
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.15% | 0.40% | €1.49B |
| iShares Ageing Population UCITS ETF2B77 | 0.14% | 0.40% | €807M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.11% | 0.30% | €2.28B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.22B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2023)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.